ethyl (1S,4R,6S,7Z,18R)-18-[7-methoxy-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,14,16-triazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylate | 922519-97-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: ethyl (1S,4R,6S,7Z,18R)-18-[7-methoxy-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,14,16-triazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylate
• CAS: 922519-97-9
• 化学式: C₃₅H₄₃N₅O₆S
• 分子量: 661.822
• InChiKey: AWHHNRVYYXXMMG-VDZATDPESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  47
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  160
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  ethyl (1S,4R,6S,7Z,18R)-18-[7-methoxy-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,14,16-triazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylate 在 甲醇 、 lithium hydroxide 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 生成 (1S,4R,6S,7Z,18R)-18-[7-methoxy-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,14,16-triazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
  参考文献：
  名称：

  WO2007/14925

  摘要：

  公开号：
• 作为产物：
  描述：

  ethyl (1R,2S)-2-ethenyl-1-[[(2S,4R)-1-(hept-6-enylcarbamoyl)-4-[7-methoxy-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxypyrrolidine-2-carbonyl]amino]cyclopropane-1-carboxylate 在 二氯(邻异丙氧基苯基亚甲基)(三环己基膦)钌 作用下， 以 1,1-二氯乙烷 为溶剂， 反应 16.0h， 以57%的产率得到ethyl (1S,4R,6S,7Z,18R)-18-[7-methoxy-2-(4-propan-2-yl-1,3-thiazol-2-yl)quinolin-4-yl]oxy-2,15-dioxo-3,14,16-triazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylate
  参考文献：
  名称：

  WO2007/14925

  摘要：

  公开号：

文献信息

• MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS
  申请人：Simmen Kenneth Alan

  公开号：US20090062311A1

  公开（公告）日：2009-03-05

  Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R 1a and R 1b are hydrogen, C 3-7 cycloalkyl, aryl, Het, C 1-6 alkoxy, C 1-6 alkyl optionally substituted with halo, C 1-6 alkoxy, cyano, polyhaloC 1-6 alkoxy, C 3-7 cycloalkyl, aryl, or with Het; or R 1a and R 1b together with the nitrogen to which they are attached form a 4 to 6 membered heterocyclic ring which may be optionally substituted; L is a direct bond, —O—, —O—C 1-4 alkanediyl-, —O—CO—, —O—C(═O)—NR 5a — or —O—C(═O)—NR 5a —C 1-4 alkanediyl-; R 2 is hydrogen, and where X is C or CH, R 2 may also be C 1-6 alkyl; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 3-7 cycloalkyl, amino, mono- or diC 1-6 alkylamino; R 4 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from O, S and N, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted with one, two or three substituents; and Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S, being optionally condensed with a benzene ring, and wherein Het may be optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).

  公式（I）及其N-氧化物、盐和立体异构体的HCV复制抑制剂，其中每个虚线表示可选的双键；X为N、CH，其中X带有双键时为C；R1a和R1b为氢、C3-7环烷基、芳基、Het、C1-6烷氧基、C1-6烷基（可选用卤代、C1-6烷氧基、氰基、多卤代C1-6烷氧基、C3-7环烷基、芳基或Het取代）、或R1a和R1b与它们所连接的氮一起形成一个4到6成员杂环环，该环可以选择性地被取代；L为直接键，-O-，-O-C1-4烷二基-，-O-CO-，-O-C（═O）-NR5a-或-O-C（═O）-NR5a-C1-4烷二基-；R2为氢，当X为C或CH时，R2也可以是C1-6烷基；R3为氢、C1-6烷基、C1-6烷氧基C1-6烷基、C3-7环烷基、氨基、单取代或二取代C1-6烷基氨基；R4为芳基或饱和、部分不饱和或完全不饱和的5或6成员单环或9到12成员的双环杂环系统，其中所述杂环系统含有一个氮，且可以选择性地含有一个到三个来自O、S和N的其他杂原子，其余环成员为碳原子；其中所述环系统可以选择性地被取代；n为3、4、5或6；p为1或2；芳基为苯基、萘基、茚基或1,2,3,4-四氢萘基，每个都可以选择性地取代一个、两个或三个取代基；Het是一个5或6成员饱和、部分不饱和或完全不饱和的杂环环，其中包含1到4个来自N、O和S的杂原子，可以选择性地与苯环融合，且Het可以选择性地取代一个、两个或三个取代基；含有化合物（I）的制药组合物和制备化合物（I）的方法。
• Macrocylic Inhibitors Of Hepatitis C Virus
  申请人：Simmen Kenneth Alan

  公开号：US20080200503A1

  公开（公告）日：2008-08-21

  Inhibitors of HCV of formula (I). and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; R 1 is hydrogen or C 1-6 alkyl; R 2 is hydrogen or C 1-6 alkyl; and n is 3, 4, 5, or 6; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
• US8008251B2
  申请人：——

  公开号：US8008251B2

  公开（公告）日：2011-08-30
• US8227407B2
  申请人：——

  公开号：US8227407B2

  公开（公告）日：2012-07-24
• WO2007/14925
  申请人：——

  公开号：——

  公开（公告）日：——